Posted by Michael Wonder on 28 Sep 2021
Onpattro (patisiran) now reimbursed in Canada for the treatment of hereditary transthyretin mediated amyloidosis
28 September 2021 - Onpattro is the only treatment that has demonstrated improvement in both polyneuropathy and quality of life measurements in patients with hATTR amyloidosis (relative to baseline).
Alnylam Pharmaceuticals is pleased to announce that Onpattro (patisiran) is now reimbursed almost everywhere in Canada for the treatment of hereditary ATTR amyloidosis with polyneuropathy.
This comes following a positive recommendation for reimbursement from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et services sociaux (INESSS).
